Page 74 - book

Product List IRANIAN PHARMACEUTICAL COMPANIES DIRECTORY

Dosage
Type Product Strength Indication Status
form
• Newly diagnosed adult and pediatric patients with (Ph+
Imatinib Capsule 100mg CML) in the chronic phase Active
• Patients with Ph+ CML in blast crisis, accelerated phase
BCR-ABL Tyrosine Kinase inhibitor Imatinib F.C. Tablet 400mg chemotherapy Active
or in the chronic phase
• Adult patients with relapsed or refractory (Ph+ ALL)
• Pediatric patients with (Ph+ ALL) in combination with
• Adult patients with (MDS/MPD) associated with PDGFR
gene rearrangements
• Adult patients with aggressive systemic mastocytosis
(ASM)
• Adult patients with hypereosinophilic syndrome (HES)
and/or chronic eosinophilic leukemia Adult patients with
dermatofibrosarcoma protuberans (DFSP)
• Patients with KIT (CD117)-positive unresectable and/or
metastatic (GIST)
• Adjuvant treatment of adult patients following complete
gross resection of KIT (CD117) Pos. GIST

• the treatment of gastrointestinal stromal tumor (GIST)
Kitent® (sunitinib) Capsule 12.5mg after disease progression on or intolerance to imatinib
mesylate.
RTKs inhibitor Kitent® (sunitinib) Capsule 25mg • the treatment of advanced renal cell carcinoma (RCC). Active
• the adjuvant treatment of adult patients at high risk of
recurrent RCC following nephrectomy.
• the treatment of progressive, well-differentiated
pancreatic neuroendocrine tumors (pNET) in patients with
Kitent® (sunitinib) Capsule 50mg unresectable locally advanced or metastatic disease.

BCR-ABL Tyrosine Kinase inhibitor Kimonil® (Nilotinib) Capsule 150mg CML-CP Active
• Adult and Pediatric Patients with Newly Diagnosed Ph+
• Adult Patients with Resistant or Intolerant Ph+ CML-CP
and CML-AP
Capsule
• Pediatric Patients with Resistant or Intolerant Ph+ CML-
200mg
Kimonil® (Nilotinib)
CP
EGFR- Tyrosine Kinase inhibitor Kimotar® F.C.Tablet 150mg • The treatment of patients with metastatic non-small cell Active
lung cancer (NSCLC) whose tumors have (EGFR) exon 19
deletions or exon 21 (L858R) substitution mutations
• in combination with gemcitabine is indicated for the
(Erlotinib)
first-line treatment of patients with locally advanced,
unresectable, or metastatic pancreatic cancer
73
you can find the rest of the product list on page 202